Catalyst Pharmaceuticals Reports Strong Fourth Quarter and F

29.02.2024 -     Achieved Record 2023 Total Revenues of $398.2 Million, an 85.9% Increase Compared to 2022 Achieved Record Fourth Quarter 2023 Total Revenues of $110.6 Million, an 82.0% Increase Compared to Fourth Quarter 2022 Reported 2023 GAAP ...

Related Keywords

Canada , Japan , United States , America , Richardj Daly , Mary Coleman , David Schull , Health Canada , Mcap Companies , Exchange Commission On , Dydo Pharma Inc , Catalyst Pharmaceuticals Inc , Devices Agency , International Number , Drug Application To Japan Pharmaceuticals , Catalyst Or Company Nasdaq , Neuroscience Commercial Portfolio , Revenues Guidance , Year Ended December , Product Revenue , Income Per Share , Cash Equivalents , Full Year , Steven Miller , Executive Vice President , Chief Operating , Scientific Officer , Jeffrey Del Carmen , Chief Commercial Officer , Michael Kalb , Chief Financial , Dydo Pharma , New Drug Application , Medical Devices Agency , Most Successful Small Cap , Annual Epilepsy Awareness , Annual Report , Exchange Commission , Canada Dial In Number , Dial In Number , Catalyst Pharmaceuticals , North America , Duchenne Muscular , Fast Track , Full Prescribing , Safety Information , Full Prescribing Information , Three Months , Investor Contact Mary Coleman , Contact David Schull , Russo Partners , Catalyst Pharmaceuticals Chart , Atalyst Pharmaceuticals Kurs , Atalyst Pharmaceuticals Aktie ,